Compound Evidence File
#EC-2026-0190
Ovagen
Filed under Peptides. The bureau holds 161 laboratory returns for this compound from 60 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
60 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 18 Mar 2026 | 1 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 28 Mar 2026 | 8 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 10.0 | 10.0 | 20 Mar 2026 | 10 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Dec 2025 | 19 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 10.0 | 10.0 | 11 Nov 2025 | 14 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Apr 2026 | 2 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Apr 2026 | 8 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Mar 2026 | 6 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 19 Jul 2026 | 12 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 10 May 2026 | 11 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Apr 2026 | 27 May 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 10.0 | 10.0 | 10.0 | 27 Jun 2026 | 12 Jul 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 10.0 | 10.0 | 10.0 | 25 Apr 2025 | 25 Apr 2025 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Mar 2026 | 10 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Mar 2026 | 24 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 9.9 | 9.9 | 10.0 | 3 Jan 2026 | 22 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Nov 2025 | 18 Feb 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 22 May 2026 | 1 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 7 Mar 2026 | 28 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Mar 2026 | 15 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 10.0 | 7 May 2026 | 27 May 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 2 Jun 2026 | 19 Aug 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 9.1 | 7.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 9.1 | 9.1 | 9.1 | 16 Mar 2025 | 16 Mar 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.6 | 7.0 | 9.7 | 24 May 2026 | 24 May 2026 |
| Peptide-SCASE #VI-2026-0111 | X | 6 | 8.5 | 6.6 | 10.0 | 20 Jun 2025 | 25 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 1 | 8.5 | 8.5 | 8.5 | 24 Apr 2025 | 24 Apr 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.3 | 6.6 | 9.4 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.2 | 7.3 | 9.5 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.1 | 7.0 | 8.7 | 21 May 2026 | 21 May 2026 |
| Pure RawzCASE #VI-2026-0767 | X | 1 | 8.0 | 8.0 | 8.0 | 21 May 2025 | 21 May 2025 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 8.0 | 8.0 | 8.0 | 17 Dec 2024 | 17 Dec 2024 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 7.7 | 7.7 | 7.7 | 21 May 2025 | 21 May 2025 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 7.4 | 7.4 | 7.4 | 8 Jul 2025 | 8 Jul 2025 |
| Shenzhen Loga Tech LG LOGACASE #VI-2026-0920 | X | 1 | 7.2 | 7.2 | 7.2 | 11 Jun 2025 | 11 Jun 2025 |
| HK PeptidesCASE #VI-2026-0140 | X | 8 | 7.0 | 5.9 | 7.9 | 24 Apr 2025 | 24 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | X | 6 | 6.6 | 3.1 | 8.1 | 9 Jun 2025 | 25 May 2026 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 3 | 6.4 | 4.5 | 7.9 | 9 Jun 2025 | 24 May 2026 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 6.4 | 5.8 | 7.1 | 11 Jun 2025 | 26 Jan 2026 |
| LSPLCASE #VI-2026-0523 | X | 3 | 6.3 | 5.3 | 7.2 | 16 Mar 2025 | 24 May 2026 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 6.1 | 6.1 | 6.1 | 25 Apr 2025 | 25 Apr 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | E | 2 | 6.0 | 6.0 | 6.1 | 27 Feb 2025 | 26 Jan 2026 |
| OupeptideCASE #VI-2026-0435 | X | 2 | 6.0 | 5.7 | 6.3 | 16 Mar 2025 | 19 Jan 2026 |
| Alpha-GenCASE #VI-2026-0905 | X | 3 | 5.9 | 5.0 | 6.9 | 21 May 2025 | 21 May 2026 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 5.9 | 5.9 | 5.9 | 11 Jun 2025 | 11 Jun 2025 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 5.7 | 5.7 | 5.7 | 21 May 2025 | 21 May 2025 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 5.4 | 5.4 | 5.4 | 17 Dec 2024 | 17 Dec 2024 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 2 | 5.2 | 4.0 | 6.4 | 28 Mar 2025 | 26 Jan 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 2 | 5.1 | 4.8 | 5.4 | 16 Mar 2025 | 24 May 2026 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 5.0 | 5.0 | 5.0 | 7 May 2025 | 7 May 2025 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 4.8 | 4.8 | 4.8 | 2 Apr 2025 | 2 Apr 2025 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 2 | 4.3 | 2.9 | 5.7 | 17 Dec 2024 | 19 Jan 2026 |
| CellupepCASE #VI-2026-0888 | X | 1 | 4.3 | 4.3 | 4.3 | 6 May 2025 | 6 May 2025 |
| YimeiCASE #VI-2026-0081 | X | 1 | 4.1 | 4.1 | 4.1 | 13 Jun 2025 | 13 Jun 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 3.3 | 3.3 | 3.3 | 27 Feb 2025 | 27 Feb 2025 |
| Zhuoyue BiotechnologyCASE #VI-2026-0632 | X | 1 | 0.9 | 0.9 | 0.9 | 28 Mar 2025 | 28 Mar 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jul 2025 | 3 Jul 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 0.0 | 0.0 | 0.0 | 25 Apr 2025 | 25 Apr 2025 |
Open any subject to view the batch-level evidence for Ovagen alone.